OP2LYSIS DEVELOPMENT
Open bankruptcyFinancials · financial year 2024, full format
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
-€116,187▲ 47.2%
2023 · -€220,008
Working capital
-€298,134
2023 · €519,809
Trend over the years
2022 to 2024, 3 financial years
The operating result stays negative: a loss of €96,440 in 2024 against €249,840 in 2023; the loss shrinks.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
Operating result-€0.1m
2024
Net result-€0.1m
2024
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Total assets€3.0m
2024
Equity€1.8m
2024
Debt€1.2m
2024
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Working capital-€0.3m
2024
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
Return on assets (ROA)-3.8%
2024
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Solvency60.1%
2024
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Current ratio0.35
2024
Average staff in full-time equivalents (FTE).
Staff (FTE)1
2024
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 72, Scientific research and development: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).
Every figure with its change against the financial year before
favourable
unfavourable
Line202220232024
Operating result-€0.2m--€0.2m▼ 41.1%-€0.1m▲ 61.4%
Net result-€0.1mwithin the sector's middle half--€0.2mwithin the sector's middle half▼ 50.5%-€0.1mwithin the sector's middle half▲ 47.2%
Equity€1.4mwithin the sector's middle half-€1.9mwithin the sector's middle half▲ 29.4%€1.8mwithin the sector's middle half▼ 2.0%
Total assets€2.9mwithin the sector's middle half-€3.2mwithin the sector's middle half▲ 9.0%€3.0mwithin the sector's middle half▼ 4.4%
Debt€1.5m-€1.3m▼ 10.9%€1.2m▼ 7.8%
Working capital€1.1mwithin the sector's middle half-€0.5mwithin the sector's middle half▼ 51.9%-€0.3mbelow the sector's middle half
Solvency49.4%within the sector's middle half-58.6%within the sector's middle half▲ 9.2pp60.1%within the sector's middle half▲ 1.5pp
Current ratio4.13within the sector's middle half-4.09within the sector's middle half▼ 0.040.35below the sector's middle half▼ 3.74
Return on assets (ROA)-5.0%within the sector's middle half--6.9%within the sector's middle half▼ 1.9pp-3.8%within the sector's middle half▲ 3.1pp
Staff (FTE)1.7below the sector's middle half-1.9below the sector's middle half▲ 11.8%1below the sector's middle half▼ 47.4%
above
within
below
the middle half of NACE 72, Scientific research and development: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €3.0m
Fixed assets
€2.9m ▲ 15.5%
Current assets
€162,970 ▼ 76.3%
Equity and liabilities €3.0m
Equity
€1.8m ▼ 2.0%
Debt
€1.2m ▼ 7.8%
Debt's share of the balance-sheet total falls from 41.4% to 39.9%. Equity and debt are lower.
Key figures and ratios
Debt to equity
0.66▼
2023 · 0.71
ROE
-6.4%▲
2023 · -11.8%
Debt ≤ 1 year
€461,104▲
2023 · €168,265
Debt > 1 year
€748,369▼
2023 · €1.1m
Income taxes
-€14,595▲
2023 · -€50,818
Staff costs
€74,344▼
2023 · €220,583
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|
| Remuneration, social security and pensions62 | €263,837 | €220,583 | €74,344 | ▼ 66.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €1,297 | €0 | - | - |
| Other operating charges640/8 | €695 | €418 | €1,735 | ▲ 315% |
| Gross operating margin9900 | €88,763 | -€28,839 | -€20,361 | ▲ 29.4% |
| Operating profit (loss)9901 | -€177,067 | -€249,840 | -€96,440 | ▲ 61.4% |
| Financial income75/76B | €1 | €747 | €2,068 | ▲ 177% |
| Recurring financial income75 | €1 | €747 | €2,068 | ▲ 177% |
| Financial charges65/66B | €19,237 | €21,733 | €36,410 | ▲ 67.5% |
| Recurring financial charges65 | €19,237 | €21,733 | €36,410 | ▲ 67.5% |
| Profit (loss) for the period before taxes9903 | -€196,303 | -€270,826 | -€130,782 | ▲ 51.7% |
| Income taxes67/77 | -€50,082 | -€50,818 | -€14,595 | ▲ 71.3% |
| Profit (loss) for the period9904 | -€146,221 | -€220,008 | -€116,187 | ▲ 47.2% |
| Profit (loss) for the period to be appropriated9905 | -€146,221 | -€220,008 | -€116,187 | ▲ 47.2% |
| Line | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|
| Assets | ||||
| Total assets20/58 | €2.9m | €3.2m | €3.0m | ▼ 4.4% |
| Fixed assets21/28 | €1.5m | €2.5m | €2.9m | ▲ 15.5% |
| Intangible fixed assets21 | €1.5m | €2.5m | €2.9m | ▲ 15.5% |
| Financial fixed assets28 | - | €0.005m | €0.005m | = |
| Current assets29/58 | €1.4m | €0.7m | €0.2m | ▼ 76.3% |
| Amounts receivable within one year40/41 | €1.3m | €0.1m | €0.1m | ▼ 5.9% |
| Trade receivables40 | €0.01m | €0 | €0.001m | - |
| Other amounts receivable41 | €1.3m | €0.1m | €0.1m | ▼ 6.7% |
| Cash at bank and in hand54/58 | €0.1m | €0.6m | €0.04m | ▼ 92.6% |
| Equity and liabilities | ||||
| Total equity and liabilities10/49 | €2.9m | €3.2m | €3.0m | ▼ 4.4% |
| Equity10/15 | €1.4m | €1.9m | €1.8m | ▼ 2.0% |
| Contributions10/11 | €1.1m | €1.5m | €1.5m | = |
| Capital10 | €1.1m | €1.5m | €1.5m | = |
| Issued capital100 | €1.1m | €1.5m | €1.5m | = |
| Profit (loss) carried forward14 | -€0.1m | -€0.4m | -€0.5m | ▼ 31.7% |
| Investment grants15 | €0.5m | €0.8m | €0.8m | ▲ 10.2% |
| Amounts payable17/49 | €1.5m | €1.3m | €1.2m | ▼ 7.8% |
| Amounts payable after more than one year17 | €1.1m | €1.1m | €0.7m | ▼ 34.6% |
| Financial debts170/4 | €1.1m | €1.1m | €0.7m | ▼ 34.6% |
| Amounts payable within one year42/48 | €0.3m | €0.2m | €0.5m | ▲ 174% |
| Financial debts43 | €0.2m | €0 | €0.3m | - |
| Credit institutions430/8 | €0.2m | €0 | €0.3m | - |
| Trade debts44 | €0.1m | €0.08m | €0.02m | ▼ 77.0% |
| Suppliers440/4 | €0.1m | €0.08m | €0.02m | ▼ 77.0% |
| Taxes, remuneration and social security45 | €0.03m | €0.01m | €0.001m | ▼ 89.3% |
| Taxes450/3 | €390 | €0.001m | €0.001m | ▲ 74.8% |
| Remuneration and social security454/9 | €0.03m | €0.009m | €93 | ▼ 99.0% |
| Other amounts payable47/48 | €0.02m | €0.08m | €0.2m | ▲ 135% |
| Accrued charges and deferred income492/3 | €0.001m | €0 | - | - |
| Line | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|
| Profit (loss) for the period9904 | -€0.1m | -€0.2m | -€0.1m | ▲ 47.2% |
| + Depreciation and write-downs630 | €0.001m | €0 | - | - |
| Operating cash flow (approximation) | -€0.1m | -€0.2m | -€0.1m | ▲ 47.2% |
| Investment in fixed assets (approximation) | - | -€1.0m | -€0.4m | ▲ 61.6% |
| Change in cash | - | €0.4m | -€0.5m | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Filings with the National Bank (3)
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2024 | full format | 18-06-2025 | 2025-00155741 |
| 31-12-2023 | full format | 13-06-2024 | 2024-00142676 |
| 31-12-2022 | full format | 28-07-2023 | 2023-00308319 |
Similar companies · same sector, comparable size
DR. JOHAN VANDEN BROUCKE
BE 0479.040.735
Ieper · equity €1,775,708
CM4Cure
BE 0765.658.810
Liège · equity €1,771,654
Wishbone
BE 0543.516.635
Flémalle · equity €1,766,378
NemaTerra
BE 0683.893.649
Grobbendonk · equity €1,762,059
NANOCYL
BE 0476.998.785
Sambreville · equity €1,892,398
Of the 760 active companies whose main activity is research and development on biotechnology (NACE 72101), figures are known for 484. 270 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector
Subsidies and aid
European research
1 projectProgrammes
Projects
To deliver the first medical treatment dedicated to patients with haemorrhagic stroke
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.